Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
6,713,803
-
Total 13F shares
-
402,082
-
Share change
-
+122,791
-
Total reported value
-
$1,271,158
-
Price per share
-
$3.16
-
Number of holders
-
18
-
Value change
-
+$424,561
-
Number of buys
-
9
-
Number of sells
-
6
Institutional Holders of Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) as of Q2 2025
As of 30 Jun 2025,
Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
402,082 shares.
The largest 10 holders included
UBS Group AG, B. Riley Wealth Advisors, Inc., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, COMMONWEALTH EQUITY SERVICES, LLC, XTX Topco Ltd, NORTHERN TRUST CORP, STATE STREET CORP, MORGAN STANLEY, and OSAIC HOLDINGS, INC..
This page lists
18
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.